Ola Melin
Directeur des opérations chez CIRCIO HOLDING ASA
Profil
Ola Melin is currently the Chief Operating Officer at Circio Holding ASA. Prior to this role, she worked as the Director of Technical Operations at OxThera AB and as the Director of Extended Manufacturing at Swedish Orphan Biovitrum AB.
Ms. Melin completed her undergraduate degree at Mälardalen University.
Postes actifs de Ola Melin
| Sociétés | Poste | Début |
|---|---|---|
| CIRCIO HOLDING ASA | Directeur des opérations | - |
Anciens postes connus de Ola Melin
| Sociétés | Poste | Fin |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Directeur Technique/Scientifique/R&D | - |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Formation de Ola Melin
| Mälardalen University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| CIRCIO HOLDING ASA | Health Technology |
| Entreprise privées | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
